Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer therapeutics - SignalRx Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - SignalRx Pharmaceuticals

Alternative Names: Delta-PI3K/BRD4 inhibitor - SignalRx; Dual PI3K inhibitors - SignalRx; Pan-PI3K/BRD4 inhibitor - SignalRx; PI3K/BRAF dual inhibitor - SignalRx; PI3K/CDK4-6/BRD4 inhibitor programme; PI3K/CDK4-6/BRD4 inhibitors - SignalRx; PI3K/HDAC dual inhibitor - SignalRx; PI3K/MEK dual inhibitor - SignalRx; PI3K/OTHER dual inhibitor - SignalRx; PI3K/PARP dual inhibitor - SignalRx; SF 2506; SF 2523; SF 2535; SF 2558HA; SF 2626; SF 5000; SRX 2523; SRX 2558; SRX 2626; SRX 3636; SRX 5000; SRX-3207

Latest Information Update: 31 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indiana University School of Medicine
  • Developer SignalRx Pharmaceuticals
  • Class Pyrones; Small molecules; Thiophenes
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; BRD4 protein inhibitors; Cyclin-dependent kinase inhibitors; DNA cytosine 5 methyltransferase inhibitors; Histone deacetylase inhibitors; Isocitrate dehydrogenase 1 inhibitors; Mitogen-activated protein kinase kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Poly(ADP-ribose) polymerase inhibitors; Proto oncogene protein b raf inhibitors; Ras signal transduction pathway inhibitors; Wnt protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 11 Dec 2021 Pharmacodynamics data from a preclinical trial in Mantle cell lymphoma (MCL) presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-2021)
  • 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in USA
  • 10 Jul 2018 SignalRx Pharmaceuticals has patent protection for thienopyranones scaffold in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top